RAPID Postmarketing Study - Medicinal Cannabis

Project Details

Introduction: The increasing availability of medicinal cannabis means that collation of data regarding efficacy and toxicity of medicinal cannabis must occur in a postmarketing, real world setting.

Title RAPID Postmarketing Study - Medicinal Cannabis

Rationale RAPID is a quality improvement program looking at the prospective use of medications and non-pharmacological interventions commonly used in palliative and supportive care. RAPID enable prospective monitoring of a medication that is already available and where the evidence underpinning its use is limited.

Key Aim To capture the benefits or effects, as well as adverse effects of medicinal cannabis.

Potential Impact Since increased availability of medicinal cannabis, the opportunity o accrue evidence of either benefit or toxicity from prescribed cannabis must be undertaken in a post-marketing context.  The data form this study will importantly inform practices that are currently being undertaken without strong evidence.

Additional information https://www.uts.edu.au/research-and-teaching/our-research/impacct/palliative-care-clinical-studies-collaborative/rapid-0-8

Researchers

Key contact: Jennifer Philip; jphilip@unimelb.edu.au

Collaborators

PaCCSC

Funding

PaCCSC